This protein was created by fusing the N-terminus of pHLIP with the C-terminus of IL-2, allowing for selective delivery to the acidic tumor microenvironment due to the low pH insertion property of pHLIP, thereby reducing the side effects. The gene discussed is IL2; the disease is neoplasm.